Charlotte Costentin
A5015037000- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis B Virus Studies
- Cancer, Lipids, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Alcohol Consumption and Health Effects
- Liver Diseases and Immunity
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Organ Transplantation Techniques and Outcomes
- Diet, Metabolism, and Disease
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- TGF-β signaling in diseases
- Cancer Immunotherapy and Biomarkers
- Genetic and Kidney Cyst Diseases
- Radiomics and Machine Learning in Medical Imaging
- Pancreatitis Pathology and Treatment
- MRI in cancer diagnosis
- HIV/AIDS drug development and treatment
- Obstructive Sleep Apnea Research
- Advanced Radiotherapy Techniques
Université Grenoble Alpes
2018-2025
Centre Hospitalier Universitaire de Grenoble
2019-2025
Inserm
2007-2025
Centre National de la Recherche Scientifique
2020-2025
Hôpital Albert Michallon
2025
Institut de Biosciences et Biotechnologies
2020-2024
Institut pour l'avancée des biosciences
2020-2024
Hotel Dieu Hospital
2021
Assistance Publique – Hôpitaux de Paris
2010-2021
Cereep Ecotron Île-de-France
2021
The prognosis of hepatocellular carcinoma (HCC) remains poor, with only one third patients eligible for curative treatments and very limited survival benefits the use sorafenib, current standard care advanced disease. Recently, agents targeting programmed death ligand 1 (PD-L1)/programmed receptor (PD-1) immune checkpoint were shown to display impressive antitumor activity in various solid or hematological malignancies, including HCC. PD-L1 immunohistochemical expression is thought represent...
We recently identified a histological subtype of hepatocellular carcinoma (HCC), designated as "macrotrabecular-massive" (MTM-HCC) and associated with specific molecular features. In order to assess the clinical relevance this variant, we investigated its prognostic value in two large series patients HCC treated by either surgical resection or radiofrequency ablation (RFA). retrospectively included 237 samples 284 liver biopsies from RFA, respectively. Histological slides were reviewed...
We assessed the activity of galunisertib, a small molecule inhibitor transforming growth factor beta (TGF-β1) receptor I, in second-line patients with hepatocellular carcinoma (HCC) two cohorts baseline serum alpha fetoprotein (AFP).Patients advanced HCC who progressed on or were ineligible to receive sorafenib, Child-Pugh A/B7 and ECOG PS ≤1 enrolled into Part A (AFP ≥ 1.5× ULN) B < ULN). Patients treated 80 150 mg galunisertib BID for 14 days per 28-day cycle. Endpoints time-to-progression...
Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. Patients outside clinical trials seldom benefit from evidence‐based monitoring. The objective this study was to estimate cost‐effectiveness complying HCC screening guidelines. economic evaluation compared surveillance cirrhosis as recommended by guidelines (“gold‐standard monitoring”) “real‐life monitoring” health care system perspective. A Markov model described history disease and treatment course...
Purpose To determine whether texture features on pretreatment contrast material-enhanced computed tomographic (CT) images can help predict overall survival (OS) and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC) treated sorafenib. Materials Methods This retrospective study included 92 HCC sorafenib between January 2009 April 2015 at two independent university hospitals. Sixty-four of the (70%) (six women, 58 men; median age, 66 years) were from institution...
Recent data suggest that alcohol-related hepatocellular carcinoma (HCC) is diagnosed at a later stage. The aim of this study was to compare HCC characteristics and outcomes in an group (group A) non-alcohol-related NA).A total 1207 patients with newly were prospectively included between May 2008 October 2009. Patients multiple causes (alcohol plus another cause) excluded. followed every year for 5 years. Recorded variables, including etiologies tested as prognostic factors survival...
Background and Aims: The European Association for the Study of Liver (EASL) has recently proposed an algorithm diagnosis advanced liver fibrosis. We aimed to evaluate diagnostic accuracy this in nonalcoholic fatty disease (NAFLD). Approach Results: One thousand fifty‐one patients with NAFLD, biopsy, four noninvasive tests (NITs; Fibrosis‐4 [FIB4], vibration controlled transient elastography [VCTE], FibroMeter, Fibrotest) were included. enhanced fibrosis (ELF) score was available 396...
Obstructive sleep apnea (OSA) induces intermittent hypoxia (IH), an independent risk factor for non-alcoholic fatty liver disease (NAFLD). While the molecular links between IH and NAFLD progression are unclear, immune cell-driven inflammation plays a crucial role in pathogenesis. Using lean mice exposed to long-term cohort of OSA patients (n = 71), we conducted comprehensive hepatic transcriptomics, lipidomics, targeted serum proteomics. Significantly, demonstrated that alone can induce NASH...